SAN FRANCISCO – Nine studies exploring a variety of trends and approaches in immuno-oncology, including adaptive cell therapies, immune checkpoint inhibitors, the use of predictive biomarkers, and more, will be presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. The meeting will take place February 28 – March 2 at the San Francisco Marriott Marquis in San Francisco, California.
Experts in immuno-oncology are available to comment on the studies below.
|
Poster Session A |
Patrick C. Gedeon, PhD |
Abstract 45: Epigenetic biomarkers for noninvasive detection of colorectal cancer.
|
Poster Session B |
Dhruvajyoti Roy Laboratory for Advanced Medicine, Inc. Irvine, California |
|
Oral Abstract Session C |
Stefan O. Ciurea, MD |
|
Welcome and General Session 1 |
Filiz Oezkan, MD |
Abstract 102: Characterizing the T cell repertoire in lung squamous cell premalignancy and its association with lesion outcome.
|
Oral Abstract Session A |
Asaf Maoz, MD |
|
Poster Session A |
Aung Tun, MBBS |
|
Poster Session A |
David D. Stenehjem, PharmD Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota Duluth, Minnesota |
|
Poster Session B |
Amod Sarnaik, MD |
Abstract 152: Isolation and characterization of exosomes from IDH mutant gliomas.
|
Poster Session B |
Nils Ludwig, DMD |
2019 ASCO-SITC Clinical Immuno-Oncology Symposium News Planning Team:
Catherine S. Magid Diefenbach, MD, American Society of Clinical Oncology (ASCO); Mario Sznol, MD, American Society of Clinical Oncology (ASCO) and Society for Immunotherapy of Cancer (SITC).
View the disclosures for the News Planning Team.
ATTRIBUTION TO THE 2019 ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM IS REQUESTED IN ALL NEWS COVERAGE.
###
About ASCO:
Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO’s Conquer Cancer Foundation supports the Society by funding groundbreaking research and education across cancer’s full continuum. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube. The Society is led by President Monica M. Bertagnolli, MD, FACS, FASCO, of the Dana-Farber/Brigham and Women’s Cancer Center, and CEO Clifford A. Hudis, MD, FACP, FASCO. Learn more about ASCO.
About the Society for Immunotherapy of Cancer:
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere.
Learn more about SITC, its educational offerings and other resources.